190 related articles for article (PubMed ID: 33048114)
1. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
2. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
3. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
4. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
[No Abstract] [Full Text] [Related]
5. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis.
Cucinotta U; Dipasquale V; Costa S; Pellegrino S; Ramistella V; Romano C
J Clin Pharm Ther; 2022 Feb; 47(2):254-256. PubMed ID: 34278581
[TBL] [Abstract][Full Text] [Related]
7. Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.
Lin E; Katz S
Inflamm Bowel Dis; 2020 Apr; 26(5):e44. PubMed ID: 32100867
[No Abstract] [Full Text] [Related]
8. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
9. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
11. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Jin Y; Lin Y; Lin LJ; Zheng CQ
World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
[TBL] [Abstract][Full Text] [Related]
14. Acneiform eruption induced by vedolizumab.
Magdaleno-Tapial J; Ferrer-Guillén B; Valenzuela-Oñate C; Esteve-Martínez A
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677821
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
16. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
17. Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis.
Dalal RS; Goksel B; Hamilton MJ
Dig Dis Sci; 2023 May; 68(5):1709-1713. PubMed ID: 36929242
[No Abstract] [Full Text] [Related]
18. Hidradenitis Suppurativa Caused by Vedolizumab.
Licata G; Gambardella A; De Rosa A; Calabrese G; Alfano R; Argenziano G
Dermatitis; 2021 Jan-Feb 01; 32(1):e23-e24. PubMed ID: 33208632
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis Induced by Vedolizumab.
Sody E; Körber A
Inflamm Bowel Dis; 2017 Feb; 23(2):E9-E11. PubMed ID: 28107281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
